All Posts Tagged With: "BDX"
(BDX) Becton, Dickinson and Company Hikes Dividend
Becton, Dickinson and Company (BDX) recently declared a quarterly dividend of 45 cents for each common share, representing a hike of 4 cents, or approximately 10%, from the preceding quarter. The company will make the dividend payment on December 30, 2011, to its shareholders...
30Nov2011 | vitalstocks | 0 comments | Continued(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook
The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures,...
18Nov2011 | vitalstocks | 0 comments | Continued(TGT) Chase Track Records If You Want to Profit
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 31, 2011: Issue #1590 Perhaps because I have time on my side, I get excited when the market sells off like it did a few weeks ago. I know that I’ll be able to buy quality stocks at a lower price. That’s especially...
12Sep2011 | InvestmentU | 0 comments | Continued(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook
June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected...
8Sep2011 | vitalstocks | 0 comments | Continued(CFN) CareFusion Buying Rowa for $150 Million
Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million. Rowa, which has customers in 30 countries, specializes in high-speed robotic medication storage and retrieval systems...
12Jul2011 | vitalstocks | 0 comments | Continued(BAX) Baxter International Presents Sustainability Report
Baxter International (BAX) recently presented its 2010 Sustainability Report. This was the 12th straight year in which the company has reported on its economic, social and environmental outcomes. This report highlights the company’s progress toward its sustainability goals...
5Jul2011 | vitalstocks | 0 comments | Continued(BDX) Unilife Completes Validation Tests
Retractable syringes maker Unilife Corporation (UNIS) has successfully completed all the required validation tests for its Unifill ready-to-fill (prefilled) syringe, representing the final step in the industrialization process of this unique device. The achievement underscores...
1Jul2011 | vitalstocks | 0 comments | Continued(BAX) Baxter International Gets Favorable Opinion for Drug
Baxter International (BAX) recently revealed that the Committee for Medicinal Products for Human Use (“CHMP”) belonging to the European Medicines Agency (“EMA”) has given a favorable opinion for extending the therapeutic indications of Kiovig to encompass a new indication...
29Jun2011 | vitalstocks | 0 comments | Continued(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook
A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011,...
22Jun2011 | vitalstocks | 0 comments | Continued(BDX) Unilife Hosts White House Business Council Meeting
Unilife Corporation (UNIS) recently hosted Kathleen Merrigan, Deputy Secretary of the U.S. Department of Agriculture (“USDA”), for a White House Business Council (“WHBC”) meeting with local business chiefs at its plant in York, Pennsylvania. The White House set up the...
22Jun2011 | vitalstocks | 0 comments | Continued(VIVO) FDA OKs Meridian C. Difficile Test
Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based...
13May2011 | vitalstocks | 0 comments | Continued(BDX) Company News for April 27, 2011 – Corporate Summary
• Hospira (NYSE:HSP) reported Q1 EPS of $0.93, well ahead of the Zacks Consensus Estimate of $0.78 per share. Revenues for the quarter fell less by than a percent to $1.0 billion, topping the Zacks Consensus Estimate of $941.0 million • Ford (NYSE:F) reported...
27Apr2011 | vitalstocks | 0 comments | Continued(BAX) Baxter International Launches Fresh Initiative To Mark World Hemophilia Day
To mark World Hemophilia Day, Baxter International (BAX) recently reiterated its determination to maintain the standard of care and ensure adequate access to treatment for victims of hemophilia and other bleeding disorders. The company is extending its hand to the World Federation...
14Apr2011 | vitalstocks | 0 comments | Continued(COV) Covidien’s Pipeline Device Cleared
Leading healthcare products maker Covidien plc (COV) has secured Premarket Approval (“PMA”) from the U.S. Food and Drug Administration’s (“FDA”) for its Pipeline Embolization Device for treating adults (22 years and above) with large, giant and wide-neck cerebral aneurysms...
13Apr2011 | vitalstocks | 0 comments | Continued(MDT) Medical Devices Industry Outlook – April 2011 – Industry Outlook
Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory...
31Mar2011 | vitalstocks | 0 comments | Continued(COV) Covidien plc Quarterly Earnings Top Expectations – Profits Skyrocket
Ireland-based health care product maker Covidien plc (COV) reported fourth-quarter fiscal 2010 (ended September 24) adjusted earnings per share of 84 cents, exceeding the Zacks Consensus Estimate of 74 cents and the year-ago earnings of 71 cents. For fiscal 2010, adjusted earnings...
12Nov2010 | vitalstocks | 0 comments | Continued(BDX) Company News for November 4, 2010 – Corporate Summary
• Qualcomm (NASDAQ:QCOM) posted better-than-expected third-quarter earnings of $0.68, up from estimates of $0.59, and revenues of $2.95 billion, that beat estimates of $2.85 billion • NRG Energy (NYSE:NRG) posted a third quarter earnings and revenue miss, with results of...
4Nov2010 | vitalstocks | 0 comments | Continued(BAX) Baxter International Introduces GLASSIA
Medical products giant Baxter International (BAX) officially commenced the U.S. launch of GLASSIA Alpha 1-Proteinase inhibitor for the treatment of emphysema. The company secured exclusive marketing rights to GLASSIA in the U.S., Canada, Australia and New Zealand from Israel-based...
3Nov2010 | vitalstocks | 0 comments | Continued(COV) Covidien Raises Quarterly Dividend by 11%
Covidien plc (COV), a leading healthcare products maker, recently enhanced shareholder returns by raising its quarterly dividend by 11% to 20 cents a share from 18 cents. The revised quarterly dividend is payable on Nov 8, 2010, to shareholders of record as on Oct 4, 2010. This...
12Oct2010 | vitalstocks | 0 comments | Continued(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test
Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. Gen-Probe is seeking FDA...
26Sep2010 | vitalstocks | 0 comments | Continued(COV) Covidien Beats The Street by a Nickel
Ireland-based healthcare product maker Covidien plc (COV) reported third-quarter fiscal 2010 results with adjusted (excluding one-time items such as restructuring charges and tax-related adjustments) earnings per share of 85 cents beating the Zacks Consensus Estimate of 80 cents...
30Jul2010 | vitalstocks | 0 comments | Continued(BAX) Baxter International to Recall Infusion Pumps
Medical product giant Baxter International Inc. (BAX) has decided to recall all of its Colleague infusion pumps in the U.S. over the next two years. The decision is based on the final order of the U.S. Food and Drug Administration (FDA). Baxter will either offer the Colleague...
15Jul2010 | vitalstocks | 0 comments | Continued(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences
Diagnostic product maker Gen-Probe Inc (GPRO) has made a $50 million strategic investment in privately-held DNA sequencing firm Pacific Biosciences (PacBio). The companies will collaborate on developing products based on their proprietary technologies. Per the deal, the companies...
5Jul2010 | vitalstocks | 0 comments | Continued(BAX) Baxter International Recalls Products
Baxter International Inc. (BAX) has recently initiated a voluntary recall of all lots of its Hylenex recombinant as a result of glass particles found in vials of the product. Hylenex increases the absorption of fluids to boost injected drugs and for fluids and drugs administered...
19May2010 | vitalstocks | 0 comments | Continued(MDT) Medical Devices Stock Review – May 2010 – Industry Outlook
The global medical devices industry is fairly large, with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic...
11May2010 | vitalstocks | 0 comments | Continued(BAX) Baxter International Analyst Downgrades the Stock
We recently downgraded Baxter International Inc. (BAX) to “Underperform” with a target price of $41 based on a P/E of roughly 10.4x our fiscal 2010 EPS estimate of $3.95. The company faces significant product recall issues and has also lowered its sales, earnings per...
5May2010 | vitalstocks | 0 comments | Continued(BDX) Becton, Dickinson and Company Earnings Tops Estimate
Becton, Dickinson and Company (BDX) reported second quarter fiscal 2010 earnings per share of $1.27, surpassing the Zacks Consensus Estimate of $1.23 and the year-ago earnings of $1.17. Sales Total revenues in the second quarter increased 7.0% year over year to $1.845 billion....
29Apr2010 | vitalstocks | 0 comments | Continued(MASI) Masimo Wins New Customer Nassau University Medical Center
Masimo Corp. (MASI) recently reported that its new customer, Nassau University Medical Center (NUMC), has completed its system-wide conversion to Masimo SET pulse oximetry technology. The conversion allows clinicians to monitor NUMC patients non-invasively using the latest pulse...
18Apr2010 | vitalstocks | 0 comments | Continued(BAX) Baxter International Posts Encouraging Clinical Study Results
Baxter International Inc. (BAX) recently produced encouraging results of its 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D (Immune Globulin Intravenous [Human]) for mild-to-moderate Alzheimer’s disease. The clinical trial measures three key parameters:...
14Apr2010 | vitalstocks | 0 comments | Continued(BAX) Baxter International Receives FDA Approval for TachoSil
Baxter International Inc. (BAX) and Nycomed recently received the U.S. Food and Drug Administration (FDA) approval of TachoSil, an absorbable fibrin sealant patch that can be used in addition to hemostasis to stop bleeding during cardiovascular surgeries. Baxter expects to launch...
7Apr2010 | vitalstocks | 0 comments | Continued